Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Antioxidants and Redox Signaling

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/ars.2015.6542PMID 27505125PMCID PMC5278809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group

  2016cited by this paper
• Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice

  2015cited by this paper
• Individual prediction of heart failure among childhood cancer survivors.

  2015cited by this paper
• Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients

  2015cited by this paper
• Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal

  2014cited by this paper
• Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model.

  2013cited by this paper
• Mito-Tempol and Dexrazoxane Exhibit Cardioprotective and Chemotherapeutic Effects through Specific Protein Oxidation and Autophagy in a Syngeneic Breast Tumor Preclinical Model

  2013cited by this paper
• Oxidative Stress and Sarcomeric Proteins

  2013cited by this paper
• Aconitase Causes Iron Toxicity in Drosophila pink1 Mutants

  2013cited by this paper
• Increased Cardiac Myocyte PDE5 Levels in Human and Murine Pressure Overload Hypertrophy Contribute to Adverse LV Remodeling

  2013cited by this paper
• Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC.

  2011cited by this paper
• Dietary nitrate supplementation protects against Doxorubicin-induced cardiomyopathy by improving mitochondrial function.

  2011cited by this paper
• The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.

  2011cited by this paper
• Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.

  2011cited by this paper
• Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic Effect

  2010cited by this paper
• Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

  2010cited by this paper
• Nitroxyl Activates SERCA in Cardiac Myocytes via Glutathiolation of Cysteine 674

  2009cited by this paper
• Long-term Results Of the Pediatric Oncology Group Studies For Childhood Acute Lymphoblastic Leukemia 1984-2001: A Report From The Children’s Oncology Group

  2009cited by this paper
• Cinaciguat (BAY 58–2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure

  2009cited by this paper
• Introducing a new entity: chemotherapy-induced arrhythmia.

  2009cited by this paper
• Toll‐like receptor‐4 deficiency attenuates doxorubicin‐induced cardiomyopathy in mice

  2008cited by this paper
• Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity

  2008cited by this paper
• Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice.

  2008cited by this paper
• Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator.

  2007cited by this paper
• Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.

  2007cited by this paper
• Cardiomyocyte-Specific Overexpression of Nitric Oxide Synthase 3 Prevents Myocardial Dysfunction in Murine Models of Septic Shock

  2007cited by this paper
• The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy.

  2007cited by this paper
• Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure

  2007cited by this paper
• Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury, Dysfunction, and Mortality Induced by Doxorubicin

  2007cited by this paper
• Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels.

  2006cited by this paper
• Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes.

  2006cited by this paper
• Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

  2005cited by this paper
• Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity

  2005cited by this paper
• Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium.

  2005cited by this paper
• Doxorubicin-induced second degree and complete atrioventricular block.

  2005cited by this paper
• S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide

  2004cited by this paper
• Congestive heart failure in patients treated with doxorubicin

  2003cited by this paper
• Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.

  2003cited by this paper
• Doxorubicin-induced persistent oxidative stress to cardiac myocytes.

  2001cited by this paper
• Endothelial Nitric Oxide Synthase Limits Left Ventricular Remodeling After Myocardial Infarction in Mice

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Impaired cell shortening and relengthening with increased pacing frequency are intrinsic to the senescent mouse cardiomyocyte.

  2000cited by this paper
• 2,7‐DICHLOROFLUORESCIN OXIDATION AND REACTIVE OXYGEN SPECIES: WHAT DOES IT MEASURE?

  2000cited by this paper
• Tissue distribution of the human soluble guanylate cyclases.

  1999cited by this paper
• Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation.

  1998cited by this paper
• Dominant negative mutants of nitric oxide-sensitive guanylyl cyclase.

  1994cited by this paper
• Acute arrhythmogenicity of doxorubicin administration

  1987cited by this paper
• Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical.

  1986cited by this paper
• Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E.

  1986cited by this paper
• Thiol-dependent DNA damage produced by anthracycline-iron complexes. The structure-activity relationships and molecular mechanisms.

  1985cited by this paper
• Early and delayed clinical cardiotoxicity of doxorubicin

  1985cited by this paper
• Free radical production from normal and adriamycin-treated rat cardiac sarcosomes.

  1985cited by this paper
• Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase.

  1983cited by this paper
• Effect of anthracycline antibiotics on oxygen radical formation in rat heart.

  1983cited by this paper
• Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin.

  1980cited by this paper
• Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.

  1977cited by this paper
• SYNTHESIS OF DIACETYLDICHLOROFLUORESCIN: A STABLE REAGENT FOR FLUOROMETRIC ANALYSIS.

  1965cited by this paper

• Vericiguat improves cardiac remodelling and function in rats with doxorubicin‐induced cardiomyopathy

  2025cites this paper
• NO/NOS system dysregulation as a key molecular mechanism in chemotherapy-induced cardiotoxicity: a review

  2025cites this paper
• Tissue-specific regulation of NO-GC isoforms in the cardiovascular system.

  2025cites this paper
• Edaravone is a Therapeutic Candidate for Doxorubicin‐Induced Cardiomyopathy by Activating the Nrf2 Pathway

  2025cites this paper
• Add-on multidrug treatment based on quadruple therapy successfully treated worsening heart failure caused by anthracycline-induced cardiomyopathy in a survivor of cancer as a young adult: a case report

  2024cites this paper
• The cardio-oncologic burden of breast cancer: molecular mechanisms and importance of preclinical models

  2024cites this paper
• Nephroprotective effects of the soluble guanylyl cyclase stimulator, riociguat in doxorubicin-induced acute kidney injury in rats

  2024cites this paper
• Vaccarin Ameliorates Doxorubicin-Induced Cardiotoxicity via Inhibition of p38 MAPK Mediated Mitochondrial Dysfunction

  2024cites this paper
• Early and dynamic detection of doxorubicin induced cardiotoxicity by myocardial contrast echocardiography combined with two-dimensional speckle tracking echocardiography in rats

  2023cites this paper
• Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy

  2023cites this paper
• Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients

  2023cites this paper
• Cellular shortening and calcium dynamics are improved by noisy stimulus in a model of cardiomyopathy

  2023cites this paper
• The sGC-cGMP Signaling Pathway as a Potential Therapeutic Target in Doxorubicin-Induced Heart Failure: A Narrative Review

  2021cites this paper
• Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician

  2021cites this paper
• Multiplicity of Nitric Oxide and Natriuretic Peptide Signalling in Heart Failure.

  2020cites this paper
• Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression

  2020cites this paper
• BAY60-2770 attenuates doxorubicin-induced cardiotoxicity by decreased oxidative stress and enhanced autophagy.

  2020cites this paper
• Shenmai Injection Protects Against Doxorubicin-Induced Cardiotoxicity via Maintaining Mitochondrial Homeostasis

  2020cites this paper
• Fluvastatin attenuates doxorubicin-induced testicular toxicity in rats by reducing oxidative stress and regulating the blood–testis barrier via mTOR signaling pathway

  2019cites this paper
• A protein nanocontainer targeting epithelial cancers: rational engineering, biochemical characterization, drug loading and cell delivery.

  2019cites this paper
• Remote Ischemic Pre-Conditioning Attenuates Adverse Cardiac Remodeling and Mortality Following Doxorubicin Administration in Mice

  2019cites this paper
• sFRP1 has a biphasic effect on doxorubicin-induced cardiotoxicity in a cellular location-dependent manner in NRCMs and Rats

  2018cites this paper
• A concise discussion of the regulatory role of cGMP kinase I in cardiac physiology and pathology

  2018cites this paper